Quimioterapia Adjuvante com CMF Modificado no Câncer Operável da Mama: Resultados de 4 anos de seguimento
DOI:
https://doi.org/10.32635/2176-9745.RBC.1986v32n4.3280Palavras-chave:
Câncer da Mama, Quimioterapia, SobrevidaResumo
Oitenta e seis pacientes com câncer de mama e linfonodos axilares positivos foram submetidos à mastectomia radical modificada seguida de quimioterapia com ciclo fosfamida e fluorouracil na dose de 600mg/m2 e methotrexate 40mg/m2, endovenosos, repetidos a cada 21 dias (CMFmod), durante seis meses (Oito ciclos). O tratamento adjuvante era iniciado no prazo máximo de 30 dias da cirurgia. O resultado do CMFmod foi comparado com grupo-controle histórico da própria instituição, constituída por 186 doentes tratadas pela mastectomia radical à Halsted e radioterapia. Decorridos 48 meses de seguimento, 72 (85%) estavam vivas e 42 (49/c) livres de doença no grupo do CMFmod e no grupo-controle 132 (7 1%) estavam vivas com 94 (51%) sem evidência de doença (p = 0,70 e p <0,25, NS). Há uma tendência para o CMFmod beneficiar as mulheres da pré-menopausa com 1 a 3 N+: sobrevida global (SV) 26/26 (10070) e intervalo livre de doença (ILD) = 21/26 (81%) quando comparado com o controle - SV: 36/44 (83%) e ILD 9 - 30/44 (68%) (p <0,15 e p <0,80, NS). Contudo, é necessário observação mais prolongada para possível ratificação dos resultados benéficos obtidos por Bonadonna com o CMF clássico com seis meses.
Downloads
Referências
Fishër B, Siack N, Ketrych D et al: Ten-year follow-up results of patients with carcinoma of the breast in a cooporetive clinical trial evaluating surgical adjuvant chemotherapy. Surg Gyn Obstet, 1975; 140: 528-534,
Nissen-Meyer A et al: Surgical adjuvant chemotherapy: results of one short course with cyciosphamide after mastectomy for breast cancer, AnnSurg, 1961; 154: 629.647. DOI: https://doi.org/10.1097/00000658-196110000-00012
Finney A. Adjuvent chemotherapy in the radical treatment of carcinoma, The Nud Med, 1971; 111: 137-141, DOI: https://doi.org/10.2214/ajr.111.1.137
Meakin JW, Alit WEC_ Beale FA et al: Ovarian irradiation and prednisone following surgery for carcinoma of the breast. In: Salmon SE, Jones SE (eds): Adjuvant Therapy of Cancer. Amsterdan, North-H olland 1977; 9-95.
Fisher B, Glass A, Redmond C et al: L-Phenylalanine musterd (L-PAM) In the management of of primary breast cancer. 1977; (suppl), 2883-2903. DOI: https://doi.org/10.1002/1097-0142(197706)39:6<2883::AID-CNCR2820390676>3.0.CO;2-9
Fisher B et al: L-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer, Cancer. 1979; 44: 847-857. DOI: https://doi.org/10.1002/1097-0142(197909)44:3<847::AID-CNCR2820440309>3.0.CO;2-3
Bonadonna G, Brusamoiino E, Valagussa P et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer, N Engi J Med, 1976; 294: 405-410. DOI: https://doi.org/10.1056/NEJM197602192940801
Rossi A, Bonadonna G, Valagussa P, Veronesi U: Muitimodal treatment in opereble breast cancer: Five-year results of the CMF programme. Br Med J. 1981; 282 (6274): 1427- 1431. DOI: https://doi.org/10.1136/bmj.282.6274.1427
Taicini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U: Adjuvant CMF in breast cancer: Comparative 5-yeer results of 12 versus 6 cycIos, J Clin Oncoi. 1983, 1 (1): 2-10. DOI: https://doi.org/10.1200/JCO.1983.1.1.2
Bonadonna G, Valagussa P, Rossi A et al. Multimodal therapy with CMF in resectable breast cancer with positive axiltary nodes: the Milan Instituto experience. Rec Results Cancer Res. 1982; 80: 149-156. DOI: https://doi.org/10.1007/978-3-642-81685-7_25
Bonadonna G, Rossi A, Tancini G et al: Adjuvant chemotherapy trials in resectabie breast cancer with positive axiliary nodes. The experience of the Milan Cancer Institute, in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 195-207.
Fisher B, Redmond C, Fisher ER et al: A summary of findings from NSABP triais of adjuvant therapy, in Jonos SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fla, Grune and Stratton, 1984; 185-194. DOI: https://doi.org/10.1007/978-3-642-82357-2_8
Morrison JM, Howeii A, Grieve RJ et al: Controlled trial of adjuvant chemotherapy for axiilary node positive breast cancer: A controiled clinicai trial, in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 283-289.
Ahmann DS: Status of adjuvant chemotherapy in patients with breast cancer. Cancr, 1984; 53: 724-728. DOI: https://doi.org/10.1002/1097-0142(19840201)53:3+<724::AID-CNCR2820531321>3.0.CO;2-8
Mlsset JL, Delgado M, Plagne A et al: Five voar results of the French adjuvant trial for breast comparing CMF to a combination of Adriamycin, Vincristine, Cyclophosphamide and 5-Fluorouracii, in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 243-251.
Senn HJ, Jungi WF, Amgwerd R et al: Results of adjuvante LMF/BCG in N+ breast cancer, in ,Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 261 -270.
Wheeler TK: Four drug combination chemotherepy following sugery for breast cancer, in Jones SE, Salmon (eds): Adjuvant Therapy of Cancer II. Orlando, Fia, Grune and Stratton 1979; 269-276.
Davis HL, MetWr GE, Ramirez G et al: An Adjuvant trial of L-Phenylaianine mustard (L-PAM) vs cyclophosphamide (C) of methotrexate (M). 5-fluorouracil (F) and vincristine (V) -CMFV following mastactomy for operable breast cancer. Proc AM Soc Clin Oncol, 1981; 22: 246. (abstr).
Tormey DC, Weinberg VE, Holland JF et al: A randomized trial of five and drug chemotherapy and chemoimmunothrepy in woman with operable nodo positivo breast cancer. J Clin Oncol, 1983; 1: 138-145, DOI: https://doi.org/10.1200/JCO.1983.1.2.138
Rubns AD, Haywerd JL, Knlght RK et al: Controlled trial of adjuvant chemotherapy with melphaian for breast cancer. Lancet 1983; 1: 839-84a DOI: https://doi.org/10.1016/S0140-6736(83)91385-5
Smlth DC, Crawford D, Dykes E et al: Adjuvant radiotherapy/chemotherepy in breast cancer, -in Jones SE, Seimor, SE (eds): Adjuvent Therapy of Cancer IV. Orlando, Fla, Grune and Stratton, 1984; 83-280.
Rlvkin SE, Giucksberg H,1 Foulkes M: Adjuvent chemotherapy for operable breast cancer with positive exillary nodes, In Jones SE, Salmon SE (eds): Adjuvant of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 209-215,
Allen H, Brooks R, Jones SE et al: Adjuvant treatment for stage II (node positive) breast cancar with Adriamycin-ciclophosphamide (Ad) + / - radiotherepy, in Salmon SE, Jones SE (eds): Adjuvant Therapy trials of MD Anderson Hospital: Results of two studios, in Jones SE. Salmon SE (eds): Adjuvant Therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 453-462.
Buzdar AU, Smith Ti.- Biumeinschhn GR et al: Breast cancer adjuvant therapy trials of MD Anderson Hospital: Adjuvant therapy of Cancer IV. Orlando, Fia, Grune and Stratton, 1984; 217-225.
Cohen E, Scanion EF, Caprini JA et al: Follow-up adjuvante chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast, Cancer, 1982; 49: 1754-1761, DOI: https://doi.org/10.1002/1097-0142(19820501)49:9<1754::AID-CNCR2820490904>3.0.CO;2-O
International Union Against Cancer. Committee on TNM Classification. TNM Clasfication of Mignant Tumors. 2nd edition. Geneva, International Union Against Cancer, 1974,
Kaplan EL, Mer P: Non parametric estimation from Incompleto observation. Am Statist Assoc J, 1958; 53: 457-481. DOI: https://doi.org/10.1080/01621459.1958.10501452
Mantel N: Evaluation of survival data and two new rank order statistic arising in its consideration. Cancer Chemother Rep, 1966; 50: 163-170,
Bonadonna G, Valagussa P: Dose-responso effect of adjuvante chemotherapy In breast cancer. N Engi J Med, 1981; 304 (1): 10-15, DOI: https://doi.org/10.1056/NEJM198101013040103
Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy triais in stage II breast cancer. J Clin Oncol, 1986; 4: 1162-1170, DOI: https://doi.org/10.1200/JCO.1986.4.8.1162
Bonadonna G, Valagussa P et al: Current status of Miian adjuvant chemotherapy trials for node-negative breast cancer. NCI Monogr, 1986; 1: 45-49.
Bonadonna G et al: Adjuvant CMF in node negative breast cancer Proc ASCO, 1986; 5: 74. DOI: https://doi.org/10.1007/BF01805984
Goldie JH, Coidman AJ, Gudaukas GA: Rationale for use of alteranating non-cros-resistant chemotherapy. Cancer Treat Rep, 1982; 66: 439-449.
Tsuruot, Nojiri M et al: Circumvention of vincristine and adrimycin resistenace in vitre and In vivo by calcium influx blockers. Cancer Res, 1983;43: 2905-2910.
Fetherston CA, Merry 5, Kaye SB et al: Verapamil enhances the sensivity to adriamycin and VP 16-213 of human lung cancer in vitro, Br J Cancer (in press).
Neville AM, Foster C, Redding H. Coombies RC: Monoclonal antibodies as probes of human breast disorders. In: Alpert & and Hiral (eds). Oncodevdopmental virology and modicine. Annals of the New York Academy of Sciences, 1983; 417: 251-261. DOI: https://doi.org/10.1111/j.1749-6632.1983.tb32868.x
Dearnely DR, Sloane JP, Ormerod MG et al: increased detection of mammary carcinoma cells in marrow smears using antisera to epitheilal membrane antigen. Br J Cancer, 1981; 44:85. DOI: https://doi.org/10.1038/bjc.1981.152
Gutterman J, Murphy EC: Investigators explore role of oncogenes In normal growth and carcinogenesis. Oncol, 1985; 30, N° 1.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
